Close

content

Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

Eli Lilly and Company announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced rate of hospitalization...

AstraZeneca acquires oral PCSK9 inhibitor programme from Dogma Therapeutics

AstraZeneca has entered into an agreement with Dogma Therapeutics to acquire its preclinical oral PCSK9 inhibitor programme. The Company aims to take the programme...

Univercells Technologies introduces the NevoLine Upstream Platform

Univercells Technologies is introducing the new generation of the NevoLine biomanufacturing product family, the NevoLine Upstream platform. This high-performance, low-footprint upstream manufacturing platform is suitable...

Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program

Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced that the U.S. FDA has...

Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 Neutralizing Antibody in COVID-19 Positive Patients

Sorrento Therapeutics, Inc. announced that it received a study may proceed letter from the FDA for its phase 1 clinical trial for COVI-GUARD (STI-1499)...

Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations

Seattle Genetics, Inc. and Merck, known as MSD outside the United States and Canada, announced two new strategic oncology collaborations. The companies will globally develop...

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read